RE:Recent Trading Activity & No response from NVCN??Try looking at the date the Company's recent share price gapped down, which is Nov 10. Titled: Neovasc Announces US$65 Million Underwritten Offering of Units Consisting of Common Shares and Warrants To Purchase Common Shares and Concurrent Private Placement of Notes and Warrants. There were also other matters regarding litigation from which 42m of the 65m will be used to settle its debt with CardiAQ , which you can view from the Nov 3 and 14 NR on SEDAR as well: "Neovasc Provides Litigation Update" and "Neovasc Announces Results for the Third Quarter of 2017". This drastic downturn is primarily the result of that court battle then the "offering" that is being used to settle its debt likely continued the drive down. The matter has been resolved and back to business.
A Value Investor who understands the fundamentals of this company and that
Neovasc is listed both on NASDAQ and the TSX with cash in the bank along with its product(s) currently "From a product perspective, our two lead devices continue to perform well, quarter after quarter; patient after patient,” commented Neovasc CEO, Alexei Marko. “Tiara has been implanted in 17 patients so far this year and 39 in total, and continues to show very encouraging results in terms of technical success and patient outcomes. For Reducer, this quarter marks a high-water mark in its commercial success in Europe and it recently was approved by the FDA to begin a pivotal study in the United States." “With the U.S. appeals process completed and the funding expected to be in place to advance our clinical priorities, our chief focus now is to advance our European pivotal trial for Tiara,” added Marko. “This 115-person study is currently screening patients at 10 clinics across the U.K., Germany and Italy. With the success the product is already achieving in compassionate use cases and in other early feasibility trials, our expectation is enrolment will proceed in a timely fashion.”
As it stands Thomson Reuters 4 Analysts Rating a Strong Buy with a 12 month projection at 3.29 average which is a 2975% increase. Thomson Reuter